Clinical Research Directory
Browse clinical research sites, groups, and studies.
Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)
Sponsor: Ruijin Hospital
Summary
This study aims to evaluate real-world treatment modalities and their corresponding effectiveness and safety in Chinese patients with marginal zone lymphoma, while also exploratively analyzing patient characteristics and health-related quality of life.
Official title: The Effectiveness and Safety of Different Treatment Modalities in Real-World Clinical Practice Among Chinese Patients with Marginal Zone Lymphoma: a Prospective, Observational, Multi-center Study
Key Details
Gender
All
Age Range
14 Years - Any
Study Type
OBSERVATIONAL
Enrollment
500
Start Date
2024-08-02
Completion Date
2029-09-01
Last Updated
2024-12-03
Healthy Volunteers
No
Conditions
Interventions
All treatment regimen selections and usage will be determined by the physician based on clinical practice and/or the respective drug labels in China.
The dosage and duration of any drug in this study will be determined by the physician based on local clinical practice and local drug labels. The drugs in this study include, but are not limited to, Obinutuzumab, Rituximab, Bruton tyrosine kinase inhibitors, and Lenalidomide. In this non-interventional study, all treatment drug usage will be determined by the physician based on clinical practice and/or the respective drug labels in China.
Locations (1)
Shanghai Ruijin Hospital
Shanghai, Shanghai Municipality, China